<PAGE>
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
---------------------
Contact: Affymetrix, Inc.
----------------
Edward M. Hurwitz Anne Bowdidge
Vice President and Director of Investor Relations
Chief Financial Officer (408) 731-5925
(408) 731-5000
AFFYMETRIX ANNOUNCES TWO-FOR-ONE STOCK SPLIT
SANTA CLARA, CA - July 21, 2000 -- Affymetrix, Inc., (NASDAQ: AFFX) announced
today that its Board of Directors has approved a two-for-one stock split of
the Company's outstanding shares of common stock.
The stock split entitles each stockholder of record at the close of business
on August 10, 2000, to receive a stock dividend of one additional share for
every share of Affymetrix Common Stock held on that date. The additional
shares resulting from the stock split will be distributed by the Company's
transfer agent on August 21, 2000.
The Company currently has approximately 27.6 million shares outstanding. Upon
completion of the split, the number will increase to approximately 55.2
million.
Affymetrix is a leader in developing and commercializing systems to acquire,
analyze and manage complex genetic information in order to improve the
quality of life. The Company's GeneChip(R) system consists of disposable DNA
probe arrays containing gene sequences on a chip, reagents for use with the
probe arrays, a scanner, and other instruments to process the probe arrays
and software to analyze and manage genetic information. The Company's spotted
array system enables individual researchers to create and analyze custom
microarrays on an easy-to-use, cost efficient platform. Additional
information on Affymetrix and GeneChip technology can be found at
www.affymetrix.com.
All statements in this press release that are not historical are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or
the like. Such statements are subject to risks and uncertainties that could
cause actual results to differ materially for Affymetrix from those
projected, including, but not limited to, uncertainties relating to
technological approaches, product development, manufacturing, market
acceptance, uncertainties related to cost and pricing of Affymetrix products,
dependence on collaborative partners, uncertainties relating to sole source
suppliers, uncertainties relating to FDA and other regulatory approvals,
competition, risks relating to intellectual property of others and the
uncertainties of patent protection and litigation. These and other risk
factors are discussed in Affymetrix' Form 10-K for the year ended December
31, 1999 and Affymetrix' other SEC reports, including its Quarterly Reports
on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims
any obligation or undertaking to release publicly any updates or revisions to
any forward-looking statements contained herein to reflect any change in
Affymetrix' expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used
by Affymetrix, Inc.
